Fixed-dose, once-weekly insulin may simplify treatment for adults with type 2 diabetes new to insulin therapy. AMR Clinical supported this phase 3 trial comparing efsitora to daily glargine. The investigational therapy was noninferior for glycemic control and showed fewer hypoglycemic events and fewer dose adjustments over 52 weeks.
Read this publication to explore:
- How weekly efsitora compares to daily glargine for A1C reduction
- Safety outcomes, including rates of hypoglycemia
- Potential advantages of fixed, less frequent insulin dosing